IMMP
Immutep Limited
Price Chart
No historical data available
Latest Quote
$0.37
-0.02 (-3.94%)
Current Price
| Previous Close | $0.38 |
| Open | $0.37 |
| Day High | $0.37 |
| Day Low | $0.36 |
| Volume | 176,999 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 147.37M |
| Total Debt | $748K |
| Cash Equivalents | $49.21M |
| Revenue | $14.24M |
| Net Income | $-56.66M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $53.94M |
| EPS (TTM) | $-0.39 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-13.89M |
| Sales | $14.24M |
| Income | $-56.66M |
| Book/sh | $0.48 |
| Cash/sh | $0.47 |
Financial Ratios
| Quick Ratio | 5.54 |
| Current Ratio | 5.69 |
| Debt/Eq | 1.70 |
Returns & Margins
| ROA | -42.45% |
| ROE | -77.31% |
| Operating Margin | -255.74% |
Ownership
| Insider Ownership | 0.01% |
| Institutional Ownership | 1.13% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.41 |
| P/S | 2.71 |
| P/B | 0.76 |
Analyst Data
| Recommendation | none |
| Target Price | $1.50 |
Technical Indicators
| SMA20 | $0.39 |
| SMA50 | $0.40 |
| SMA200 | $1.32 |
| RSI | 45.45 |
| ATR | 0.0193 |
| Shares Float | 143.03M |
| Short Float | 0.53% |
| Short Ratio | 3.96 |
| Volatility | 2.19 |
| Rel Volume | 1.47 |
Performance History
| Week | -5.13% |
| Month | -2.63% |
| Quarter | -15.91% |
| 6 Months | -86.79% |
| YTD | -87.46% |
| Year | -77.71% |
| 3 Years | -78.86% |
| 5 Years | -88.89% |
| 10 Years | -86.94% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
đ° Latest News
Is Immutep (ASX:IMM) In A Good Position To Deliver On Growth Plans?
Simply Wall St. âĸ 2026-05-10T22:03:05Z
Immutep Limited (IMMP) Receives FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
Insider Monkey âĸ 2026-04-21T02:47:43Z
Sector Update: Health Care Stocks Decline Late Afternoon
MT Newswires âĸ 2026-04-15T19:56:37ZSector Update: Health Care Stocks Lower in Afternoon Trading
MT Newswires âĸ 2026-04-15T17:55:11ZAdobe downgraded, Nio upgraded: Wall Streetâs top analyst calls
TipRanks âĸ 2026-03-14T13:42:16Z
Immutepâs LAG-3 hopes take a hit on Phase III NSCLC termination
Clinical Trials Arena âĸ 2026-03-13T19:02:13Z
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure
BioPharma Dive âĸ 2026-03-13T10:17:00Z
3 ASX Penny Stocks With Market Caps Under A$600M
Simply Wall St. âĸ 2026-02-18T03:05:08Z
Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 50% of the company
Simply Wall St. âĸ 2026-02-09T20:48:25Z
Dr. Reddy's Laboratories Q3 Earnings Call Highlights
MarketBeat âĸ 2026-01-21T17:14:37Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | - | $0 | $0 | $122,216 |
| Operating Revenue | - | $0 | $0 | $122,216 |
| Expenses | ||||
| Interest Expense | - | $21,947 | $14,635 | $66,306 |
| Total Expenses | - | $33,398,466 | $29,721,165 | $24,395,772 |
| Other Income Expense | - | $-8,125 | $442,151 | $1,072,063 |
| Other Non Operating Income Expenses | - | $-89,515 | $-99,747 | $-232,953 |
| Net Non Operating Interest Income Expense | - | $2,763,388 | $658,966 | $94,756 |
| Interest Expense Non Operating | - | $21,947 | $14,635 | $66,306 |
| Operating Expense | - | $33,398,466 | $29,721,165 | $24,395,772 |
| Other Operating Expenses | - | $-2,756,009 | $-2,514,865 | $-3,259,679 |
| General And Administrative Expense | - | $6,350,513 | $6,226,571 | $5,172,255 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | - | $-30,643,202 | $-28,620,048 | $-23,106,761 |
| Net Interest Income | - | $2,763,388 | $658,966 | $94,756 |
| Interest Income | - | $2,785,335 | $673,600 | $161,062 |
| Normalized Income | - | $-30,724,593 | $-29,161,947 | $-24,020,272 |
| Net Income From Continuing And Discontinued Operation | - | $-30,643,202 | $-28,620,048 | $-23,106,761 |
| Net Income Common Stockholders | - | $-30,643,202 | $-28,620,048 | $-23,106,761 |
| Net Income | - | $-30,643,202 | $-28,620,048 | $-23,106,761 |
| Net Income Including Noncontrolling Interests | - | $-30,643,202 | $-28,620,048 | $-23,106,761 |
| Net Income Continuous Operations | - | $-30,643,202 | $-28,620,048 | $-23,106,761 |
| Pretax Income | - | $-30,643,202 | $-28,620,048 | $-23,106,737 |
| Interest Income Non Operating | - | $2,785,335 | $673,600 | $161,062 |
| Operating Income | - | $-33,398,466 | $-29,721,165 | $-24,273,556 |
| Per Share | ||||
| Diluted EPS | $-0.30 | $-0.26 | $-0.32 | $-0.27 |
| Basic EPS | $-0.30 | $-0.26 | $-0.32 | $-0.27 |
| Other | ||||
| Diluted Average Shares | $104,434,606 | $86,159,391 | $64,017,202 | $62,431,934 |
| Basic Average Shares | $104,434,606 | $86,159,391 | $64,017,202 | $60,901,582 |
| Tax Effect Of Unusual Items | - | $0 | $0 | $391,505 |
| Tax Rate For Calcs | - | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | - | $-30,702,646 | $-29,147,312 | $-24,345,447 |
| Total Unusual Items | - | $81,390 | $541,899 | $1,305,016 |
| Total Unusual Items Excluding Goodwill | - | $81,390 | $541,899 | $1,305,016 |
| EBITDA (Bullshit earnings) | - | $-30,621,255 | $-28,605,413 | $-23,040,431 |
| EBIT | - | $-30,621,255 | $-28,605,413 | $-23,040,431 |
| Diluted NI Availto Com Stockholders | - | $-30,643,202 | $-28,620,048 | $-23,106,761 |
| Tax Provision | - | $0 | $0 | $24 |
| Gain On Sale Of Security | - | $81,390 | $541,899 | $1,305,016 |
| Research And Development | - | $29,803,962 | $26,009,459 | $22,483,196 |
| Selling General And Administration | - | $6,350,513 | $6,226,571 | $5,172,255 |
| Other Gand A | - | $6,350,513 | $6,226,571 | $5,172,255 |
| Reconciled Depreciation | - | - | - | $2,151,803 |
Fetched: 2026-09-01
Balance Sheet (Annual)
| Metric | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $130,043,616 | $91,089,788 | $59,916,280 | $41,663,357 |
| Total Assets | $144,604,933 | $105,774,022 | $73,292,359 | $56,561,082 |
| Total Non Current Assets | $7,337,761 | $8,955,270 | $8,147,640 | $9,385,053 |
| Non Current Prepaid Assets | $938,435 | $1,811,270 | $355,567 | $313,170 |
| Goodwill And Other Intangible Assets | $5,911,719 | $6,807,907 | $7,571,069 | $8,858,339 |
| Other Intangible Assets | $5,832,837 | $6,729,024 | $7,492,186 | $8,782,519 |
| Current Assets | $137,267,172 | $96,818,753 | $65,144,719 | $47,176,029 |
| Restricted Cash | $0 | $0 | $0 | $320,623 |
| Prepaid Assets | $1,374,071 | $2,564,199 | $1,752,483 | $1,173,406 |
| Receivables | $5,422,189 | $5,719,608 | $6,006,922 | $4,222,858 |
| Other Receivables | $4,520,735 | $4,347,721 | $4,496,309 | $3,652,707 |
| Taxes Receivable | $897,694 | $1,278,145 | $1,498,131 | $534,648 |
| Accounts Receivable | $3,760 | $93,742 | $12,452 | $35,379 |
| Cash Cash Equivalents And Short Term Investments | $130,470,912 | $88,534,945 | $57,385,314 | $41,459,142 |
| Cash And Cash Equivalents | $116,061,796 | $88,534,945 | $57,385,314 | $41,459,142 |
| Cash Equivalents | $47,960,467 | $2,574,034 | $216,643 | $5,710,947 |
| Cash Financial | $68,101,329 | $85,960,911 | $57,168,670 | $35,748,195 |
| Accrued Interest Receivable | - | $15,117 | $31 | $123 |
| Debt | ||||
| Total Debt | $1,143,322 | $881,110 | $1,243,773 | $1,941,100 |
| Long Term Debt And Capital Lease Obligation | $975,733 | $748,252 | $1,119,399 | $1,797,547 |
| Long Term Debt | $689,213 | $599,316 | $1,042,288 | $1,742,309 |
| Current Debt And Capital Lease Obligation | $167,589 | $132,859 | $124,374 | $143,552 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,649,597 | $7,876,328 | $5,805,010 | $6,039,387 |
| Total Non Current Liabilities Net Minority Interest | $1,127,107 | $866,209 | $1,203,511 | $2,357,350 |
| Non Current Deferred Liabilities | $0 | $0 | $0 | $0 |
| Non Current Deferred Taxes Liabilities | $0 | $0 | $0 | $0 |
| Current Liabilities | $7,522,491 | $7,010,119 | $4,601,499 | $3,682,037 |
| Payables And Accrued Expenses | $6,859,516 | $6,473,888 | $4,126,390 | $3,297,062 |
| Payables | $3,026,488 | $4,162,881 | $4,126,390 | $3,297,062 |
| Other Payable | $307,538 | $254,550 | $2,070,333 | $2,038,770 |
| Accounts Payable | $2,718,950 | $3,908,331 | $2,056,057 | $1,258,292 |
| Derivative Product Liabilities | - | $0 | $0 | $498,494 |
| Other Current Liabilities | - | - | $94,617 | - |
| Equity | ||||
| Common Stock Equity | $135,955,336 | $97,897,695 | $67,487,349 | $50,521,695 |
| Total Equity Gross Minority Interest | $135,955,336 | $97,897,695 | $67,487,349 | $50,521,695 |
| Stockholders Equity | $135,955,336 | $97,897,695 | $67,487,349 | $50,521,695 |
| Gains Losses Not Affecting Retained Earnings | $21,566,507 | $21,612,423 | $20,806,899 | $23,782,340 |
| Retained Earnings | $-274,495,803 | $-243,852,600 | $-216,883,216 | $-189,369,257 |
| Other | ||||
| Ordinary Shares Number | $1,042,046,098 | $859,591,645 | $637,020,747 | $528,823,539 |
| Share Issued | $1,042,046,098 | $859,591,645 | $637,020,747 | $528,823,539 |
| Tangible Book Value | $130,043,616 | $91,089,788 | $59,916,280 | $41,663,357 |
| Invested Capital | $136,644,549 | $98,497,010 | $68,529,637 | $52,264,004 |
| Working Capital | $129,744,682 | $89,808,634 | $60,543,220 | $43,493,992 |
| Capital Lease Obligations | $454,109 | $281,795 | $201,484 | $198,791 |
| Total Capitalization | $136,644,549 | $98,497,010 | $68,529,637 | $52,264,004 |
| Capital Stock | $388,884,631 | $320,137,872 | $263,563,665 | $216,108,613 |
| Common Stock | $388,884,631 | $320,137,872 | $263,563,665 | $216,108,613 |
| Employee Benefits | $145,752 | $117,957 | $84,112 | $61,308 |
| Long Term Capital Lease Obligation | $286,520 | $148,936 | $77,110 | $55,239 |
| Long Term Provisions | $5,622 | - | - | - |
| Current Capital Lease Obligation | $167,589 | $132,859 | $124,374 | $143,552 |
| Pensionand Other Post Retirement Benefit Plans Current | $495,386 | $403,372 | $256,118 | $241,422 |
| Current Accrued Expenses | $3,833,028 | $2,311,007 | - | - |
| Goodwill | $78,882 | $78,882 | $78,882 | $75,820 |
| Net PPE | $487,606 | $336,093 | $221,004 | $213,545 |
| Accumulated Depreciation | $-496,422 | $-462,486 | $-454,084 | $-434,122 |
| Gross PPE | $984,028 | $798,579 | $675,088 | $647,667 |
| Machinery Furniture Equipment | $541,720 | $522,131 | $481,296 | $462,317 |
| Buildings And Improvements | $442,308 | $276,448 | $193,793 | $185,350 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $14,409,116 | $0 | - | - |
Fetched: 2026-09-01
Cash Flow Statement (Annual)
| Metric | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,648,205 | $-25,422,205 | $-21,702,056 | $-12,173,994 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $-24,979,360 | $-25,362,855 | $-21,685,618 | $-12,163,237 |
| Classesof Cash Receiptsfrom Operating Activities | $2,842,156 | $2,681,582 | $2,494,265 | $1,223,812 |
| Other Cash Receiptsfrom Operating Activities | $142,933 | $59,052 | $62,403 | $222,427 |
| Operating Cash Flow | - | - | $-31,523,949 | - |
| Cash Flow From Continuing Operating Activities | - | - | $-31,523,949 | - |
| Operating Gains Losses | - | - | $-347,021 | - |
| Investing Activities | ||||
| Capital Expenditure | $-668,844 | $-59,351 | $-16,438 | $-10,757 |
| Investing Cash Flow | $-15,077,960 | $-59,351 | $-16,438 | $-10,757 |
| Cash Flow From Continuing Investing Activities | $-15,077,960 | $-59,351 | $-16,438 | $-10,757 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $71,904,976 | $57,448,171 | $38,002,388 | $29,860,880 |
| Financing Cash Flow | $68,278,385 | $54,535,176 | $36,101,605 | $36,323,469 |
| Cash Flow From Continuing Financing Activities | $68,278,385 | $54,535,176 | $36,101,605 | $36,323,469 |
| Net Other Financing Charges | $-3,464,113 | $-2,760,933 | $-1,741,144 | $-1,157,939 |
| Net Common Stock Issuance | $71,904,976 | $57,448,171 | $38,002,388 | $29,860,880 |
| Common Stock Issuance | $71,904,976 | $57,448,171 | $38,002,388 | $29,860,880 |
| Other | ||||
| Repayment Of Debt | $-162,478 | $-152,062 | $-159,638 | $-147,816 |
| End Cash Position | $116,061,796 | $88,534,945 | $57,385,314 | $41,779,766 |
| Beginning Cash Position | $88,534,945 | $57,385,314 | $43,467,138 | $18,149,382 |
| Effect Of Exchange Rate Changes | $-694,213 | $2,036,661 | $-481,374 | $-519,091 |
| Changes In Cash | $28,221,064 | $29,112,970 | $14,399,550 | $24,149,475 |
| Net Issuance Payments Of Debt | $-162,478 | $-152,062 | $-159,638 | $-147,816 |
| Net Long Term Debt Issuance | $-162,478 | $-152,062 | $-159,638 | $-147,816 |
| Long Term Debt Payments | $-162,478 | $-152,062 | $-159,638 | $-147,816 |
| Net Investment Purchase And Sale | $-14,409,116 | $0 | $0 | - |
| Purchase Of Investment | $-14,409,116 | $0 | $0 | - |
| Net Intangibles Purchase And Sale | $-647,887 | $0 | $0 | - |
| Purchase Of Intangibles | $-647,887 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-20,958 | $-59,351 | $-16,438 | $-10,757 |
| Purchase Of PPE | $-20,958 | $-59,351 | $-16,438 | $-10,757 |
| Taxes Refund Paid Direct | $0 | $0 | $-24 | $-23 |
| Interest Received Direct | $2,651,072 | $658,534 | $161,159 | $77,393 |
| Interest Paid Direct | $-21,527 | $-14,735 | $-66,306 | $-9,070 |
| Classesof Cash Payments | $-30,451,060 | $-28,688,236 | $-24,274,737 | $-13,455,373 |
| Paymentsto Suppliersfor Goodsand Services | $-30,451,060 | $-28,688,236 | $-24,274,713 | $-13,455,350 |
| Receiptsfrom Government Grants | $2,699,222 | $2,622,530 | $2,368,867 | $906,017 |
| Receiptsfrom Customers | $0 | $0 | $62,996 | $95,368 |
| Proceeds From Stock Option Exercised | - | $0 | $0 | $7,768,345 |
| Change In Working Capital | - | - | $-1,628,029 | - |
| Change In Other Working Capital | - | - | $36,739 | - |
| Change In Other Current Assets | - | - | $-816,006 | - |
| Change In Payables And Accrued Expense | - | - | $1,496,914 | - |
| Change In Payable | - | - | $1,496,914 | - |
| Change In Receivables | - | - | $-2,345,676 | - |
| Other Non Cash Items | - | - | $338,639 | - |
| Stock Based Compensation | - | - | $1,550,496 | - |
| Depreciation Amortization Depletion | - | - | $2,151,803 | - |
| Depreciation And Amortization | - | - | $2,151,803 | - |
| Gain Loss On Investment Securities | - | - | $-616,375 | - |
| Net Foreign Currency Exchange Gain Loss | - | - | $269,354 | - |
| Net Income From Continuing Operations | - | - | $-33,589,837 | - |
Fetched: 2026-09-01